Latest Drug Development Stories
Initial Phase 1 Safety Study Successfully Completed, Building on Promising Body of Preclinical Data CUPERTINO, Calif., March 2, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX)
-- Conference Call and Webcast Scheduled for Today at 5:00 p.m. Eastern Time -- SAN DIEGO, March 2, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
WEST HAVEN, Conn., Feb. 25, 2015 /PRNewswire/ -- NanoViricides, Inc.
Although pharmaceutical companies recognize that promising new drugs that are toxic to adult stem cells are likely to fail, the industry has been unable to do much about this problem, which is
BETHLEHEM, Pa., Feb.
GLEN BURNIE, Md., Feb.
SCOTTSDALE, Ariz., Feb. 10, 2015 /PRNewswire/ -- MCLife is creating a movement with #CFShoeSelfie to raise awareness about cystic fibrosis and raise funds for the Cystic Fibrosis Foundation.
RESEARCH TRIANGLE PARK, N.C., Feb.
The two companies are in the early planning stages of pursuing shared business development opportunities that can deliver synergistic advantages to their respective customers. Frederick,
The Alliance for Clinical Research Excellence and Safety (ACRES) welcomes Dr.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.